3Arroyo V, Jimenez W. Complications of cirrhosis. Ⅱ Renal and circulatory dysfunction. Lights and shadows in an important clinical problem.J Hepatol, 2000, 32 (1): 157-170.
4Wong F, Blendis L. The pathophysiologic basis for the treatment of cirrhotic ascites: Clin Liver Dis, 2001, 5 (3) : 819 -832.
5Martin PY, Sehrier RW. Pathogenesis of water and sodium retention in cirrhosis. Kidenty Int Suppl, 1997, 59 (6): 43-49.
7Decaux G.Difference is solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985[].Journal of Laboratory and Clinical Medicine.2001
8Gadano A,Moreau R,Pessione F,et al.Aquaretic effects of niravoline, a kappa-opioid agonist, in patients with cirrhosis[].Journal of Hepatology.2000
9Gines P,Jimenez W.Aquaretic agent: a new potential treatment of dilutional hyponatremia in cirrhosis[].Journal of Hepatology.1996
10Gines P,Jimenez W.Aquaretic agents: a new potential treatment of dilutional hyponatremia in cirrhosis[].Journal of Hepatology.1996
3Narahara Y, Kanazawa H, Sakamoto C, et al. The efficacy and safetofterli- ressin and albumin in patients with type 1 hepatorenal syndrome:a multi- center, open-label, explorativestudy [ J ]. Gastroenterol, 2012,47 ( 3 ) : 313 -320.
